Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Courses
Press/Media
Search by expertise, name or affiliation
Fluoxetine and reversal of multidrug resistance
Dan Peer
,
Rimona Margalit
*
*
Corresponding author for this work
The Shmunis School of Biomedicine and Cancer Research
Biochemistry Molecular Biology
Harvard University
Research output
:
Contribution to journal
›
Review article
›
peer-review
70
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Fluoxetine and reversal of multidrug resistance'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multidrug Resistance
100%
Fluoxetine
100%
Chemosensitizer
100%
Multidrug Resistance Reversal
100%
Multi-pumping
66%
Three-generation
33%
ATP-binding Cassette Transporter A1 (ABCA1)
33%
Cancer Stem Cells
33%
Cancer multidrug Resistance
33%
Resistance Mechanisms
33%
Resistance Trends
33%
Antidepressant Fluoxetine
33%
Chemosensitization
33%
Prozac
33%
Resistance Reversal Agents
33%
Medicine and Dentistry
Multidrug Resistance
100%
Fluoxetine
100%
Chemosensitizer
50%
Malignant Neoplasm
16%
In Vitro
16%
Cancer Stem Cell
16%
Antidepressant
16%
Chemosensitization
16%
Neuroscience
Fluoxetine
100%
Chemosensitizer
100%
In Vivo
33%
Antidepressant
33%
In Vitro
33%
Cancer Stem Cell
33%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Drug Resistance
100%
Fluoxetine
100%
Malignant Neoplasm
33%
Antidepressant
16%